Literature DB >> 21387288

Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.

Victor Chun Lam Wong1, Han Chen, Josephine Mun Yee Ko, Kwok Wah Chan, Yuen Piu Chan, Simon Law, Daniel Chua, Dora Lai-Wan Kwong, Hong Lok Lung, Gopesh Srivastava, Johnny Cheuk On Tang, Sai Wah Tsao, Eugene R Zabarovsky, Eric J Stanbridge, Maria Li Lung.   

Abstract

Suppressive effects of DUSP6 in tumorigenesis and EMT-associated properties were observed. Dual-specificity phosphatase (DUSP6) is a MAP kinase phosphatase (MKP) negatively regulating the activity of ERK, one of the major molecular switches in the MAPK signaling cascade propagating the signaling responses during malignancies. The impact of DUSP6 in EMT and its contribution to tumor dissemination has not yet been characterized. Due to differences in tumor microenvironments affecting cell signaling during cancer progression, DUSP6 may play varying roles in tumor development. We sought to examine the potential role of DUSP6-mediated tumorigenesis and EMT-associated properties in two aerodigestive tract cancers, namely, esophageal squamous cell carcinoma (ESCC) and nasopharyngeal carcinoma (NPC). Significant loss of DUSP6 was observed in 100% of 11 ESCC cell lines and 71% of seven NPC cell lines. DUSP6 expression was down-regulated in 40% of 30 ESCC tumor tissues and 75% of 20 NPC tumor tissues compared to their respective normal counterparts. Suppressive effects of DUSP6 in tumor formation and cancer cell mobility are seen in in vivo tumorigenicity assay and in vitro colony formation, three-dimensional Matrigel culture, cell migration and invasion chamber tests. Notably, overexpression of DUSP6 impairs EMT-associated properties. Furthermore, tissue microarray analysis reveals a clinical association of DUSP6 expression with better patient survival. Taken together, our study provides a novel insight into understanding the functional impact of DUSP6 in tumorigenesis and metastasis of ESCC and NPC.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387288     DOI: 10.1002/ijc.25970

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.

Authors:  Seyedmehdi Shojaee; Rebecca Caeser; Maike Buchner; Eugene Park; Srividya Swaminathan; Christian Hurtz; Huimin Geng; Lai N Chan; Lars Klemm; Wolf-Karsten Hofmann; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Elisabeth Paietta; Jeffery Molkentin; H Phillip Koeffler; Cheryl L Willman; Stephen P Hunger; Ari Melnick; Steven M Kornblau; Markus Müschen
Journal:  Cancer Cell       Date:  2015-06-11       Impact factor: 31.743

2.  Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

Authors:  C Vanesa Díaz-García; Alba Agudo-López; Carlos Pérez; Elena Prieto-García; Lara Iglesias; Santiago Ponce; Analia Rodríguez Garzotto; José L Rodríguez-Peralto; Hernán Cortés-Funes; José A López-Martín; M Teresa Agulló-Ortuño
Journal:  Tumour Biol       Date:  2014-10-25

Review 3.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

4.  Abrogated expression of DEC1 during oesophageal squamous cell carcinoma progression is age- and family history-related and significantly associated with lymph node metastasis.

Authors:  V C L Wong; J M Y Ko; R Z Qi; P J Li; L D Wang; J-L Li; Y P Chan; K W Chan; E J Stanbridge; M L Lung
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

5.  Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma.

Authors:  Xiaobin Cui; Su Li; Tingting Li; Xuelian Pang; Shumao Zhang; Jing Jin; Jianming Hu; Chunxia Liu; Lan Yang; Hao Peng; Jinfang Jiang; Weihua Liang; Jing Suo; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.

Authors:  Janine M Buonato; Matthew J Lazzara
Journal:  Cancer Res       Date:  2013-10-09       Impact factor: 12.701

7.  Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.

Authors:  Young H Lee; Bethanie L Morrison; Donald P Bottaro
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

8.  COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.

Authors:  Ze-Lei Li; Shu-Biao Ye; Li-Yin OuYang; Han Zhang; Yu-Shan Chen; Jia He; Qiu-Yan Chen; Chao-Nan Qian; Xiao-Shi Zhang; Jun Cui; Yi-Xin Zeng; Jiang Li
Journal:  Oncoimmunology       Date:  2015-07-09       Impact factor: 8.110

9.  Identification of an Apis cerana cerana MAP kinase phosphatase 3 gene (AccMKP3) in response to environmental stress.

Authors:  Yuzhen Chao; Chen Wang; Haihong Jia; Na Zhai; Hongfang Wang; Baohua Xu; Han Li; Xingqi Guo
Journal:  Cell Stress Chaperones       Date:  2019-10-29       Impact factor: 3.667

10.  SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma.

Authors:  H L Lung; O Y Man; M C Yeung; J M Y Ko; A K L Cheung; E W L Law; Z Yu; W H Shuen; E Tung; S H K Chan; D K Bangarusamy; Y Cheng; X Yang; R Kan; Y Phoon; K C Chan; D Chua; D L Kwong; A W M Lee; M F Ji; M L Lung
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.